GOLDMAN SACHS GROUP INC - NEUROCRINE BIOSCIENCES INC ownership

NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 39 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of NEUROCRINE BIOSCIENCES INC
ValueSharesWeighting
Q1 2022$13,100,000
+5.1%
10,000,0000.0%0.00%
+50.0%
Q4 2021$12,469,000
-6.0%
10,000,0000.0%0.00%
-33.3%
Q3 2021$13,258,000
-0.8%
10,000,0000.0%0.00%0.0%
Q2 2021$13,369,000
-0.6%
10,000,0000.0%0.00%0.0%
Q1 2021$13,444,000
+6182.2%
10,000,000
+6656.8%
0.00%
Q2 2018$214,000148,0000.00%
Other shareholders
NEUROCRINE BIOSCIENCES INC shareholders Q2 2022
NameSharesValueWeighting ↓
III Capital Management 12,500,000$17,262,0003.12%
CSS LLC/IL 24,395,000$33,616,0001.59%
Mint Tower Capital Management B.V. 9,000,000$12,407,0001.46%
Context Partners Fund, L.P. 3,000,000$4,125,0000.90%
Context Capital Management, LLC 3,000,000$4,125,0000.90%
SHENKMAN CAPITAL MANAGEMENT INC 4,258,000$5,971,0000.71%
SSI INVESTMENT MANAGEMENT LLC 5,888,000$8,100,0000.70%
Aequim Alternative Investments LP 3,000,000$4,155,0000.55%
WOLVERINE ASSET MANAGEMENT LLC 32,181,000$44,437,0000.40%
TWO SIGMA SECURITIES, LLC 13,000,000$17,875,0000.36%
View complete list of NEUROCRINE BIOSCIENCES INC shareholders